BRPI0510500A - composições farmacêuticas - Google Patents

composições farmacêuticas

Info

Publication number
BRPI0510500A
BRPI0510500A BRPI0510500-5A BRPI0510500A BRPI0510500A BR PI0510500 A BRPI0510500 A BR PI0510500A BR PI0510500 A BRPI0510500 A BR PI0510500A BR PI0510500 A BRPI0510500 A BR PI0510500A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions
relates
present
glycopyrrolate
Prior art date
Application number
BRPI0510500-5A
Other languages
English (en)
Inventor
David Morton
Martin Shott
Rebecca Davies
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510500(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of BRPI0510500A publication Critical patent/BRPI0510500A/pt
Publication of BRPI0510500B1 publication Critical patent/BRPI0510500B1/pt
Publication of BRPI0510500B8 publication Critical patent/BRPI0510500B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS. A presente invenção refere-se a composições farmacêuticas que compreendem o agente antimuscarínico glicopirrolato, por exemplo, o sal brometo de glicopirrónio. Em particular, a presente invenção refere-se a composições em pó seco que exibem estabilidade aperfeiçoada com o tempo, e a métodos para produzir essas composições.
BRPI0510500A 2004-04-30 2005-04-29 formulação de pó seco, seu método de preparação e dispositivo de inalação de pó seco BRPI0510500B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
GB0409703.6 2004-04-30
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
BRPI0510500A true BRPI0510500A (pt) 2007-10-30
BRPI0510500B1 BRPI0510500B1 (pt) 2019-04-24
BRPI0510500B8 BRPI0510500B8 (pt) 2021-05-25

Family

ID=32408337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510500A BRPI0510500B8 (pt) 2004-04-30 2005-04-29 formulação de pó seco, seu método de preparação e dispositivo de inalação de pó seco

Country Status (27)

Country Link
US (1) US20080063719A1 (pt)
EP (3) EP1755555B1 (pt)
JP (2) JP5000483B2 (pt)
KR (1) KR101287919B1 (pt)
CN (3) CN102008453A (pt)
AU (2) AU2005237266B2 (pt)
BR (1) BRPI0510500B8 (pt)
CA (1) CA2563760C (pt)
CY (6) CY1113069T1 (pt)
DK (2) DK1755555T3 (pt)
ES (2) ES2546982T3 (pt)
GB (1) GB0409703D0 (pt)
HK (2) HK1095282A1 (pt)
HU (4) HUE025463T2 (pt)
IL (2) IL178651A (pt)
LT (1) LTC2422766I2 (pt)
LU (2) LU92176I2 (pt)
MX (2) MXPA06012493A (pt)
NO (1) NO20065502L (pt)
NZ (1) NZ550479A (pt)
PL (2) PL2422766T3 (pt)
PT (2) PT1755555E (pt)
RU (1) RU2396943C2 (pt)
SG (3) SG186673A1 (pt)
SI (2) SI2422766T1 (pt)
WO (1) WO2005105043A2 (pt)
ZA (1) ZA200609350B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CN101896162B (zh) * 2007-12-13 2013-06-05 诺瓦提斯公司 有机化合物
PL2229148T3 (pl) * 2007-12-13 2014-08-29 Novartis Ag Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej
EP3311820A1 (en) * 2008-02-26 2018-04-25 Sunovion Respiratory Development Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP3578169A1 (en) 2009-02-26 2019-12-11 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
AU2010238641A1 (en) * 2009-04-24 2011-11-10 Merck Sharp & Dohme Corp. Agglomerate formulations useful in dry powder inhalers
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
MX2012011179A (es) * 2010-03-31 2013-03-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica en polvo para inhalacion.
CA2794941C (en) 2010-04-01 2018-05-15 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
SI2560611T1 (en) 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. A process for preparing particles with reduced electrostatic charges
JP5792307B2 (ja) 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 水分制御特性を示す乾燥粉末吸入薬物製品及びその投与方法
JP5792308B2 (ja) 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 水分制御特性を示す乾燥粉末吸入薬物製品及びその投与方法
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
CA2902795C (en) 2013-02-28 2021-06-15 Dermira, Inc. Glycopyrrolate salts
KR102391332B1 (ko) † 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
AR102305A1 (es) 2014-10-16 2017-02-15 Teva Branded Pharmaceutical Products R&D Inc Procedimiento para preparar formulación farmacéutica inhalable de polvo seco
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CA3016488C (en) 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
JP6741773B2 (ja) 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 炎症状態の急性増悪の治療のための投与レジメン
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
US11219602B2 (en) 2017-03-15 2022-01-11 Vectura Limited Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
JP7280627B2 (ja) 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR20200078162A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US7744855B2 (en) 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP2298279B1 (en) * 2000-11-30 2018-11-14 Vectura Limited Pharmaceutical compositions for inhalation
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
JP2005530765A (ja) * 2002-05-07 2005-10-13 ネクター セラピューティクス 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
EP1861361A1 (en) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use

Also Published As

Publication number Publication date
BRPI0510500B1 (pt) 2019-04-24
CY2013012I1 (el) 2015-08-05
RU2006142322A (ru) 2008-06-20
EP1755555B1 (en) 2012-05-23
CN102008453A (zh) 2011-04-13
HUE025463T2 (en) 2016-02-29
CN1964700A (zh) 2007-05-16
SI1755555T1 (sl) 2012-10-30
US20080063719A1 (en) 2008-03-13
ES2388289T3 (es) 2012-10-11
EP2422766A2 (en) 2012-02-29
EP2422767A3 (en) 2012-04-25
CY2014015I2 (el) 2015-12-09
PT2422766E (pt) 2015-10-12
CY2014015I1 (el) 2015-12-09
PL1755555T3 (pl) 2012-11-30
DK1755555T3 (da) 2012-08-20
HUS1500072I1 (hu) 2016-02-29
CY2015060I1 (el) 2020-05-29
WO2005105043A2 (en) 2005-11-10
MX341426B (es) 2016-08-18
LU92392I2 (fr) 2015-11-02
EP2422767A2 (en) 2012-02-29
HUS1300006I1 (hu) 2016-07-28
SI2422766T1 (sl) 2015-10-30
CA2563760A1 (en) 2005-11-10
IL178651A (en) 2012-12-31
LU92176I2 (fr) 2013-05-27
AU2005237266A1 (en) 2005-11-10
CY2013012I2 (el) 2015-08-05
SG152292A1 (en) 2009-05-29
JP5000483B2 (ja) 2012-08-15
BRPI0510500B8 (pt) 2021-05-25
EP2422766B1 (en) 2015-06-24
IL178651A0 (en) 2007-02-11
CA2563760C (en) 2013-07-02
IL223545A0 (en) 2013-02-03
ES2546982T3 (es) 2015-09-30
AU2005237266B2 (en) 2010-11-11
HUS1500073I1 (hu) 2016-02-29
NO20065502L (no) 2007-01-24
RU2396943C2 (ru) 2010-08-20
AU2011200543A1 (en) 2011-03-03
EP2422766A3 (en) 2012-04-25
NZ550479A (en) 2009-11-27
WO2005105043A3 (en) 2006-05-04
SG10201605001SA (en) 2016-08-30
CN107252423A (zh) 2017-10-17
IL223545A (en) 2016-04-21
DK2422766T3 (da) 2015-08-31
KR101287919B1 (ko) 2013-07-18
HK1095282A1 (en) 2007-05-04
PL2422766T3 (pl) 2015-11-30
LTC2422766I2 (lt) 2020-02-10
MXPA06012493A (es) 2007-01-29
CY2015059I1 (el) 2020-05-29
AU2011200543B2 (en) 2012-11-29
JP2007535522A (ja) 2007-12-06
ZA200609350B (en) 2008-04-30
SG186673A1 (en) 2013-01-30
HK1167334A1 (en) 2012-11-30
CY1116655T1 (el) 2017-03-15
LU92176I9 (pt) 2019-01-04
KR20070033978A (ko) 2007-03-27
GB0409703D0 (en) 2004-06-02
AU2011200543A8 (en) 2011-03-31
JP2012031209A (ja) 2012-02-16
CY1113069T1 (el) 2015-08-05
PT1755555E (pt) 2012-08-17
JP5124718B2 (ja) 2013-01-23
EP1755555A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
BRPI0510500A (pt) composições farmacêuticas
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
ECSP078057A (es) Formulaciones de estrógenos conjugados y bazedoxifeno
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
BRPI0508403A (pt) produtos de pelìcula tendo propriedades de desintegração controlada
NO20072839L (no) 4-hydroksybenzomorfaner
WO2008075101A3 (en) Improvements relating to laser marking
GT200600520A (es) Agentes antibacterianos
WO2006081252A3 (en) Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
BRPI0508359A (pt) composições de pelìcula
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
UY30520A1 (es) Compuestos de pirimidina
BRPI0408221A (pt) dispositivos dispensadores
BRPI0608287A2 (pt) agente endoparasiticida
CL2004001473A1 (es) Procedimiento para producir neuronas desde celulas mesenquimatosas no diferenciadas y composicion que las contiene.
TW200730190A (en) New combination to treat liver fibrosis
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
ATE506988T1 (de) Haarstreckzusammensetzung mit einem disaccharid
EA200501818A1 (ru) Индазолы, обладающие анальгетической активностью
CL2008000673A1 (es) Compuestos derivados de aril sulfonamidas; metodo para preparar dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer de ovario, entre otras enfermedades.
DE50202121D1 (de) Metallsalze als antimykotika
EA200900266A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
BRPI0414423A (pt) inibidores de pace4, suas composições farmacêuticas e respectivos usos
FR2882517B1 (fr) Composition cosmetique contenant un compose tribochrome, procede mettant en oeuvre cette composition et utilisations

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF